**Question:** Olcegepant, mechanism of action is:

A. Inhibition of calcitonin gene-related peptide (CGRP) release
B. Inhibition of prostaglandin synthesis
C. Blockade of calcium channels
D. Inhibition of substance P release

**Core Concept:**
Olcegepant is a drug that belongs to a class of medications called calcitonin gene-related peptide (CGRP) antagonists. CGRP is a neuropeptide involved in the transmission of pain signals in the nervous system, particularly in the context of migraine pain. The primary mechanism of action of olcegepant is the inhibition of CGRP release, which helps to reduce migraine attacks in patients suffering from migraine with aura or migraine without aura.

**Why the Correct Answer is Right:**
Olcegepant targets CGRP, a key mediator in the transmission of pain signals in migraines. By inhibiting the release of CGRP, olcegepant works to reduce migraine attacks in patients.

**Why Each Wrong Option is Incorrect:**
A. Inhibition of prostaglandin synthesis is incorrect because prostaglandins are involved in inflammation and pain, while CGRP is the primary target for migraine treatment.
B. Blockade of calcium channels is also incorrect as this mechanism is not relevant to the treatment of migraines, which are primarily mediated by neuropeptides like CGRP.
C. Inhibition of substance P release is incorrect because substance P is involved in nociception (pain transmission) but does not play a significant role in migraine pathogenesis.

**Clinical Pearl:**
CGRP antagonists like olcegepant represent a novel approach to migraine treatment, targeting a specific neuropeptide involved in migraine pain transmission. This class of medications can be particularly useful for patients with migraines resistant to traditional treatments, contributing to the advancement of migraine management strategies.